A high LDH to AST ratio helps to differentiate pregnancy-associated thrombotic thrombocytopenic purpura (TTP) from HELLP syndrome

References

• Martin JN Jr, Bailey AP, Rehberg JF, Owens MT, Keiser SD, May WL. Thrombotic thrombocytopenic purpura in 166 pregnancies: 1955–2006. Am J Obstet Gynecol 2008;199:98–104.
   PubMed Web of Science ®Google Scholar
• Rehberg JF, Briery CM, Hudson WT, Bofill JA, Martin JN Jr. Thrombotic thrombocytopenic purpura masquerading as hemolysis, elevated liver enzymes, low platelets (HELLP) syndrome in late pregnancy. Obstet Gynecol 2006;108:817–820.
   PubMed Web of Science ®Google Scholar
• Kaiser C, Distler W. Thrombotic thrombocytopenic purpura and HELLP (hemolysis, elevated liver enzymes, and low platelets) syndrome: Differential diagnostic problems. Am J Obstet Gynecol 1996;175:506–507.
   PubMed Web of Science ®Google Scholar
• Sibai BM. Imitators of severe preeclampsia. Obstet Gynecol 2007;109:956–966.
   PubMed Web of Science ®Google Scholar
• Martin JN Jr, Rinehart BK, May WL, Magann EF, Terrone DA, Blake PG. The spectrum of severe preeclampsia: Comparative analysis by HELLP (hemolysis, elevated liver enzyme levels, and low platelet count) syndrome classification. Am J Obstet Gynecol 1999;180:1373–1384.
   PubMed Web of Science ®Google Scholar
• Martin JN Jr, Rose CH, Briery CM. Understanding and managing HELLP syndrome: The integral role of aggressive glucocorticoids for mother and child. Am J Obstet Gynecol 2006;195:914–934.
   PubMed Web of Science ®Google Scholar
• Martin JN Jr, Owens MY, Keiser SD, Parrish MR, Tam Tam KB, Brewer JM, Cushman JL, May WL. Standardized Mississippi protocol treatment of 190 patients with HELLP syndrome: Slowing disease progression and preventing new major maternal morbidity. Hypertens Pregnancy 2011 Jan 10. (Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Nguyen TC, Stegmayr B, Busund R, Bunchman TE, Carcillo JA. Plasma therapies in thrombotic syndromes. Int J Artif Organs 2005;28:459–465.
   PubMed Web of Science ®Google Scholar
• Moake JL. Thrombotic microangiopathies: Mechanisms of disease. N Engl J Med 2002;347:589–600.
   PubMed Web of Science ®Google Scholar
• George JN. Thrombotic thrombocytopenic purpura. N Engl J Med 2006;354:1927–1935.
   PubMed Web of Science ®Google Scholar
• Owens MY, Martin JN Jr, Keiser SD, et al. Postpartum multiorgan microangiopathic syndrome (PMMS): A recognizable clinical scenario common to multiple uncommon diseases requiring plasma exchange to enable recovery. J Clin Apher. (submitted for publication).
   Google Scholar
• George JN. ADAMTS13: What it does, how it works, and why it’s important. Transfusion 2009;49:196–198.
   PubMed Web of Science ®Google Scholar
• George JN, Vesely SK. ADAMTS13 and TTP: the clot thickens. Blood 2004;103:3997–3998.
   Web of Science ®Google Scholar
• Keiser SD, Owens MY, Parrish MR, Cushman JL, Bufkin L, May WL, Martin JN Jr. HELLP syndrome with and without eclampsia. Am J Perinatol 2011;28:187–194.
   PubMed Web of Science ®Google Scholar
• Crowther MA, George JN. Thrombotic thrombocytopenic purpura: 2008 update. Cleve Clin J Med 2008;75:369–375.
   PubMed Web of Science ®Google Scholar
• Chauhan AK, Motto DG, Lamb CB, Bergmeier W, Dockal M, Plaimauer B, Scheiflinger F, et al. Systemic antithrombotic effects of ADAMTS13. J Exp Med 2006;203:767–776.
   PubMed Web of Science ®Google Scholar
• Uemura M, Tatsumi K, Matsumoto M, Fujimoto M, Matsuyama T, Ishikawa M, Iwamoto TA, et al. Localization of ADAMTS13 to the stellate cells of human liver. Blood 2005;106:922–924.
   PubMed Web of Science ®Google Scholar
• Shang D, Zheng XW, Niiya M, Zheng XL. Apical sorting of ADAMTS13 in vascular endothelial cells and Madin-Darby canine kidney cells depends on the CUB domains and their association with lipid rafts. Blood 2006;108:2207–2215.
   PubMed Web of Science ®Google Scholar
• Young B, Levine RJ, Salahuddin S, et al. The use of angiogenic biomarkers to differentiate non-HELLP related thrombocytopenia from HELLP syndrome. J Matern Fetal Neonatal Med 2009;17:1–6.
   Google Scholar
• Ono T, Mimuro J, Madoiwa S, Soejima K, Kashiwakura Y, Ishiwata A, Takano K, et al. Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: Its correlation with development of renal failure. Blood 2006;107:528–534.
   PubMed Web of Science ®Google Scholar
• Martin JN Jr, Briery CM, Rose CH, Owens MT, Bofill JA, Files JC. Postpartum plasma exchange as adjunctive therapy for severe acute fatty liver of pregnancy. J Clin Apher 2008;23:138–143.
   PubMed Web of Science ®Google Scholar
• Martin JN Jr, Files JC, Blake PG, Norman PH, Martin RW, Hess LW, Morrison JC, Wiser WL. Plasma exchange for preeclampsia. I. Postpartum use for persistently severe preeclampsia-eclampsia with HELLP syndrome. Am J Obstet Gynecol 1990;162:126–137.
   PubMed Web of Science ®Google Scholar
• Martin JN Jr, Files JC, Blake PG, Perry KG Jr, Morrison JC, Norman PH. Postpartum plasma exchange for atypical preeclampsia-eclampsia as HELLP (hemolysis, elevated liver enzymes, and low platelets) syndrome. Am J Obstet Gynecol 1995;172:1107–25; discussion 1125.
   Web of Science ®Google Scholar
• Lattuada A, Rossi E, Calzarossa C, Candolfi R, Mannucci PM. Mild to moderate reduction of a von Willebrand factor cleaving protease (ADAMTS-13) in pregnant women with HELLP microangiopathic syndrome. Haematologica 2003;88:1029–1034.
   PubMed Web of Science ®Google Scholar
• Hulstein JJ, van Runnard Heimel PJ, Franx A, Lenting PJ, Bruinse HW, Silence K, de Groot PG, Fijnheer R. Acute activation of the endothelium results in increased levels of active von Willebrand factor in hemolysis, elevated liver enzymes and low platelets (HELLP) syndrome. J Thromb Haemost 2006;4:2569–2575.
   PubMed Web of Science ®Google Scholar
• Meyer SC, Sulzer I, Lämmle B, Kremer Hovinga JA. Hyperbilirubinemia interferes with ADAMTS-13 activity measurement by FRETS-VWF73 assay: Diagnostic relevance in patients suffering from acute thrombotic microangiopathies. J Thromb Haemost 2007;5:866–867.
   PubMed Web of Science ®Google Scholar
• Dwyre DM, Dursteler B, Nashelsky M, Friedman KD, Raife TJ. Value of ADAMTS13 activity and inhibitor in the postmortem diagnosis of thrombotic thrombocytopenic purpura. J Clin Apher 2009;24:106–110.
   PubMed Web of Science ®Google Scholar
• McCarthy LJ, Dlott JS, Orazi A, Waxman D, Miraglia CC, Danielson CF. Thrombotic thrombocytopenic purpura: Yesterday, today, tomorrow. Ther Apher Dial 2004;8:80–86.
   PubMed Web of Science ®Google Scholar